Patents by Inventor Jennifer N. Tran

Jennifer N. Tran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS Modulating Compounds
    Publication number: 20240383922
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: April 10, 2024
    Publication date: November 21, 2024
    Inventors: Wilian Augusto Cortopassi Coelho, Chaodi Dai, Katherine De La Fuente, Julie Farand, Juan A. Guerrero, Tezcan Guney, Hongyan Guo, Safaa S. Jamshed, Darryl Kato, Irene N. Kiburu, Scott E. Lazerwith, James B.C. Mack, Joshua L. Martin, Jessica L. McKinley, Jonathan William Medley, Hyung-Jung Pyun, Thomas P. Stratton, Rhiannon Thomas-Tran, Maoqun Tian, Vickie H. Tsui, William J. Watkins, Jie Xu, Adam D. Zajdlik, Jennifer R. Zhang
  • Certain alkylene diamine-substituted heterocycles
    Publication number: 20040229870
    Abstract: The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor.
    Type: Application
    Filed: November 10, 2003
    Publication date: November 18, 2004
    Applicants: NEUROGEN CORPORATION, PFIZER INC.
    Inventors: Raymond F. Horvath, Jennifer N. Tran, Stephane De Lombaert, Kevin J. Hodgetts, Philip A. Carpino, David A. Griffith
  • Certain alkylene diamine-substituted heterocycles
    Patent number: 6696445
    Abstract: The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. The present invention provides novel, potent, non-peptidic antagonists of NPY receptors, particularly, the NPY1 receptors, designed from a selection of mono-, bi-, or tri-cyclic heterocyclic cores. This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. The novel compounds encompassed by the present invention are those of the formula I-XV.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: February 24, 2004
    Assignees: Neurogen Corporation, Pfizer Inc.
    Inventors: Raymond F. Horvath, Jennifer N Tran, Stéphane De Lombaert, Kevin J. Hodgetts, Philip A. Carpino, David A. Griffith
  • Certain alkylene diamine-substituted heterocycles
    Publication number: 20030158197
    Abstract: The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor.
    Type: Application
    Filed: November 8, 2002
    Publication date: August 21, 2003
    Applicant: NEUROGEN CORPORATION
    Inventors: Raymond F. Horvath, Jennifer N. Tran, Stephane De Lombaert, Kevin J. Hodgetts, Philip A. Carpino, David A. Griffith
  • Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines
    Publication number: 20030069246
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: February 25, 2002
    Publication date: April 10, 2003
    Applicant: Neurogen Corporation
    Inventors: James W. Darrow, Stephane J. De Lombaert, Charles A. Blum, Jennifer N. Tran, Mark A. Giangiordano, David Andrew Griffith, Philip Albert Carpino
  • 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
    Patent number: 6486164
    Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof wherein: R1, R2, R3, R4 and R5 are the same or different and represent hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C4 alkylthio, hydroxy, amino, mono- or di(C1-C6)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy; and X is oxygen, a bond, C1-C2 alkylene, or methyleneoxy, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: November 26, 2002
    Assignee: Neurogen Corporation
    Inventors: Jennifer N. Tran, Andrew Thurkauf
  • 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkypiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
    Publication number: 20020099056
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: December 20, 2001
    Publication date: July 25, 2002
    Applicant: Neurogen Corporation
    Inventors: Jennifer N. Tran, Andrew Thurkauf
  • 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
    Patent number: 6333329
    Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof wherein: R1, R2, R3, R4 and R5 are the same or different and represent hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C4 alkylthio, hydroxy, amino, mono- or di(C1-C6)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy; and X is oxygen, a bond, C1-C2 alkylene, or methyleneoxy, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.
    Type: Grant
    Filed: January 16, 2001
    Date of Patent: December 25, 2001
    Assignee: Neurogen Corporation
    Inventors: Jennifer N. Tran, Andrew Thurkauf
  • 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
    Publication number: 20010005753
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: January 16, 2001
    Publication date: June 28, 2001
    Applicant: Neurogen Corporation
    Inventors: Jennifer N. Tran, Andrew Thurkauf
  • 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
    Patent number: 6177566
    Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof wherein: R1, R2, R3, R4 and R5 are the same or different and represent hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C4 alkylthio, hydroxy, amino, mono- or di(C1-C6)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy; and X is oxygen, a bond, C1-C2 alkylene, or methyleneoxy, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: January 23, 2001
    Assignee: Neurogen Corporation
    Inventors: Jennifer N. Tran, Andrew Thurkauf